All blog posts
Total 167 results for
Showing 12 out of 167 results
27 апреля 2026
The EU Pharma Package is finally here – here's the settled position on key areas
12 марта 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
19 января 2026
Where is the UPC after two and a half years - and what to expect in 2026?
15 декабря 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
26 ноября 2025
FRAND interim licensing – where are the limits?
03 сентября 2025
UPC Court of Appeal confirms that late-filed costs applications are inadmissible and in refusing reference to the CJEU provides guidance on what it will refer
31 июля 2025
EU Regulatory Reform for Medicinal Products: Bolar exemption
21 июля 2025
Trends emerging as the UPC enters its third year
13 мая 2025
EU Regulatory Reform for Medicinal Products: Changes to MAs, supply, and transparency
30 апреля 2025
EU Regulatory Reform for Medicinal Products: Review of new regulatory exclusivities
12 февраля 2025
European Commission shelves proposed SEP regulation
05 ноября 2024
Regulation of SEPs in Europe – where are we now?
Showing 12 out of 167 results
View moreKey contacts
Rebekah Gay
Partner, Head of Intellectual Property, Sydney
Laura Orlando
Managing Partner, Milan Office, Milan
Sue Gilchrist
Consultant, Sydney
Peng Lei
Partner, Herbert Smith Freehills Kramer Kewei Joint Operation, Mainland China and Shanghai
Alexandra Neri
Partner, Paris
Dr Ina vom Feld
Partner, Germany
Sebastian Moore
Partner, Head Intellectual Property, London and Milan
Rachel Montagnon
Knowledge Counsel, London